There is a continuing need for methods and compositions relating to hormone-receptor-dependent cancers, including pharmaceutical compositions including one or more compounds having activity against steroid hormone-receptor-dependent cancer and methods of treatment of a steroid hormone-receptor-dependent cancer in a subject using said pharmaceutical compositions. ELK1 Is a steroid hormone receptor tethering, protein that is implicated in hormone receptor dependent cancers. Compositions and methods according to aspects of the present invention inhibit the association of steroid hormone receptors with ELKL providing activity against steroid hormone-receptor-dependent cancer. Such compositions are provided including any one or more of: chemical compound structures I, II, III, IV, V, Vi, VII, one or more derivatives, and/or one or more: pharmaceutically acceptable esters and/or one or more pharmaceutically acceptable salts, of any thereof, wherein a pharmaceutically acceptable carrier may be included in the compositions.
